D
Dora Kholodenko
Researcher at Élan
Publications - 19
Citations - 12952
Dora Kholodenko is an academic researcher from Élan. The author has contributed to research in topics: P3 peptide & Gamma secretase. The author has an hindex of 14, co-authored 19 publications receiving 12534 citations. Previous affiliations of Dora Kholodenko include Sunesis Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
Dale Schenk,Robin Barbour,Whitney Dunn,Grace Gordon,Henry Grajeda,Teresa Guido,Kang Hu,Jiping Huang,Kelly Johnson-Wood,Karen Khan,Dora Kholodenko,Michael K. Lee,Zhenmei Liao,Ivan Lieberburg,Ruth Motter,Linda Mutter,Ferdie Soriano,George Shopp,Vasquez Nicki J,Christopher Vandevert,Shannan Walker,Mark Wogulis,Ted Yednock,Dora Games,Peter Seubert +24 more
TL;DR: It is reported that immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis, and treatment of the older animals markedly reduced the extent and progression of these AD-like neuropathologies.
Journal ArticleDOI
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.
Frederique Bard,Catherine Cannon,Robin Barbour,Rae Lyn Burke,Dora Games,Henry Grajeda,Teresa Guido,Kang Hu,Jiping Huang,Kelly Johnson-Wood,Karen Khan,Dora Kholodenko,Michael K. Lee,Ivan Lieberburg,Ruth Motter,Minh Nguyen,Ferdie Soriano,Vasquez Nicki J,Kim Weiss,Brent Welch,Peter Seubert,Dale Schenk,Ted Yednock +22 more
TL;DR: Results indicate that antibodies can cross the blood–brain barrier to act directly in the central nervous system and should be considered as a therapeutic approach for the treatment of Alzheimer disease and other neurological disorders.
Journal ArticleDOI
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.
Lennart Mucke,Eliezer Masliah,Gui-Qiu Yu,Margaret Mallory,Edward Rockenstein,Gwen Tatsuno,Kang Hu,Dora Kholodenko,Kelly Johnson-Wood,Lisa McConlogue +9 more
TL;DR: It is concluded that Aβ is synaptotoxic even in the absence of plaques and that high levels of Aβ1–42 are insufficient to induce plaque formation in mice expressing wild-type hAPP, supporting the emerging view that plaque-independent Aβ toxicity plays an important role in the development of synaptic deficits in AD and related conditions.
Journal ArticleDOI
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
Martin Citron,David Westaway,Weiming Xia,George A. Carlson,Thekla S. Diehl,G. Levesque,Kelly Johnson-Wood,Michael K. Lee,Peter Seubert,Angela Davis,Dora Kholodenko,Ruth Motter,R. Sherrington,Billie J. Perry,Hong Yao,Robert Strome,Ivan Lieberburg,Johanna M. Rommens,Soyeon Kim,Dale Schenk,Paul E. Fraser,Peter St. George Hyslop,Dennis J. Selkoe +22 more
TL;DR: The data demonstrate that the preseniiin mutations cause a dominant gain of function and may induce AD by enhancing Aβ42 production, thus promoting cerebral β-amyloidosis.
Journal ArticleDOI
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models.
Albert Y. Hsia,Eliezer Masliah,Lisa McConlogue,Gui Qiu Yu,Gwen Tatsuno,Kang Hu,Dora Kholodenko,Robert C. Malenka,Roger A. Nicoll,Lennart Mucke +9 more
TL;DR: It is shown that overexpression of FAD(717V-->F)-mutant human APP in neurons of transgenic mice decreases the density of presynaptic terminals and neurons well before these mice develop amyloid plaques, suggesting a neurotoxic effect of Abeta that is independent of plaque formation.